PHILADELPHIA, PA--(BUSINESS WIRE)— Context Therapeutics, a clinical stage biopharmaceutical company dedicated to the treatment of hormone driven cancers, today announces it has signed multiple research collaborations to further understand the role of progesterone receptor (PR) signaling and its blockade to overcome resistance mechanisms underlying metastatic breast cancer (mBCa).

PHILADELPHIA, Pa.--(BUSINESS WIRE)—Context Therapeutics, a clinical-stage biopharmaceutical company focused on hormonally-driven cancers, announced that CEO Martin Lehr is a semifinalist for Ernst, & Young’s (EY) 2018 Entrepreneur of the Year for the Philadelphia region.

PHILADELPHIA, PA--Context Therapeutics, a clinical stage biopharmaceutical company announced that it has acquired worldwide rights to Apristor.